Search research articles
Contact Us
Filters
Showing results (451-460 of 583) with videos related to
Page
of 59
Sort By:
Neuroscience
|
February 10, 2019
Functionalized Phenylbenzamides Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury
George W Farr, Christopher H Hall, Susan M Farr, et al.
Current Oncology (Toronto, Ont.)
|
May 26, 2026
Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients
Raeef Rahman, Anas Zayad, Carmel Awadallah, et al.
Critical Reviews in Oncology/Hematology
|
February 29, 2024
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis
Moazzam Shahzad, Qamar Iqbal, Ezza Tariq, et al.
Hematology/Oncology and Stem Cell Therapy
|
April 1, 2024
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review
Moazzam Shahzad, Muhammad Fareed Khalid, Muhammad Kashif Amin, et al.
Blood Advances
|
February 5, 2024
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Armin Ghobadi, Javier Munoz, Jason R Westin, et al.
Blood Cancer Journal
|
May 31, 2024
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy
Danai Dima, Al-Ola Abdallah, James A Davis, et al.
Cancers
|
November 13, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals
Jordan Snyder, Shebli Atrash, Barry Paul, et al.
Frontiers in Immunology
|
October 20, 2022
Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis
Muhammad Umair Mushtaq, Moazzam Shahzad, Amna Y Shah, et al.
ESMO Open
|
July 9, 2021
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
V Subbiah, S Kuravi, S Ganguly, et al.
Leukemia & Lymphoma
|
June 10, 2022
Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis
Razwana Khanam, Moazzam Shahzad, Sibgha Gull Chaudhary, et al.
Page
of 59
Search research articles
Search
Showing results (451-460 of 583) with videos related to
Sort By:
Page
of 59
Neuroscience
|
February 10, 2019
Functionalized Phenylbenzamides Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury
George W Farr, Christopher H Hall, Susan M Farr, et al.
Current Oncology (Toronto, Ont.)
|
May 26, 2026
Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients
Raeef Rahman, Anas Zayad, Carmel Awadallah, et al.
Critical Reviews in Oncology/Hematology
|
February 29, 2024
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis
Moazzam Shahzad, Qamar Iqbal, Ezza Tariq, et al.
Hematology/Oncology and Stem Cell Therapy
|
April 1, 2024
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review
Moazzam Shahzad, Muhammad Fareed Khalid, Muhammad Kashif Amin, et al.
Blood Advances
|
February 5, 2024
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Armin Ghobadi, Javier Munoz, Jason R Westin, et al.
Blood Cancer Journal
|
May 31, 2024
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy
Danai Dima, Al-Ola Abdallah, James A Davis, et al.
Cancers
|
November 13, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals
Jordan Snyder, Shebli Atrash, Barry Paul, et al.
Frontiers in Immunology
|
October 20, 2022
Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis
Muhammad Umair Mushtaq, Moazzam Shahzad, Amna Y Shah, et al.
ESMO Open
|
July 9, 2021
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
V Subbiah, S Kuravi, S Ganguly, et al.
Leukemia & Lymphoma
|
June 10, 2022
Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis
Razwana Khanam, Moazzam Shahzad, Sibgha Gull Chaudhary, et al.
Page
of 59